GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » Cyclically Adjusted PB Ratio

Tenax Therapeutics (FRA:YBO0) Cyclically Adjusted PB Ratio : 0.00 (As of May. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Tenax Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-28), Tenax Therapeutics's current share price is €161.60. Tenax Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €1,087,060.00. Tenax Therapeutics's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Tenax Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Tenax Therapeutics's highest Cyclically Adjusted PB Ratio was 18.90. The lowest was 0.01. And the median was 0.15.

FRA:YBO0's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Tenax Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €5.840. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1,087,060.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Tenax Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Tenax Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Cyclically Adjusted PB Ratio Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.08 0.05 0.01 -

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tenax Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Tenax Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Cyclically Adjusted PB Ratio falls into.



Tenax Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Tenax Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=161.60/1087060
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Tenax Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.84/131.7762*131.7762
=5.840

Current CPI (Mar. 2024) = 131.7762.

Tenax Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201404 68,975.862 100.023 90,872.687
201407 68,472.727 100.520 89,763.806
201410 69,563.636 100.176 91,507.720
201501 73,736.364 98.604 98,543.133
201504 73,950.000 99.824 97,620.703
201507 69,593.182 100.691 91,078.174
201510 64,729.545 100.346 85,003.682
201603 56,464.773 100.470 74,058.760
201606 51,472.727 101.688 66,702.794
201609 47,276.136 101.861 61,160.499
201612 18,465.909 101.863 23,888.698
201703 14,995.455 102.862 19,210.595
201706 11,394.318 103.349 14,528.428
201709 9,690.909 104.136 12,263.157
201712 8,528.409 104.011 10,805.013
201803 7,130.769 105.290 8,924.590
201806 5,862.637 106.317 7,266.547
201809 4,600.000 106.507 5,691.384
201812 4,366.245 105.998 5,428.100
201903 2,376.883 107.251 2,920.421
201906 1,829.496 108.070 2,230.824
201909 1,409.976 108.329 1,715.151
201912 806.413 108.420 980.132
202003 618.800 108.902 748.779
202006 426.307 108.767 516.489
202009 796.705 109.815 956.034
202012 482.003 109.897 577.965
202103 277.885 111.754 327.671
202106 77.524 114.631 89.119
202109 390.667 115.734 444.817
202112 238.540 117.630 267.228
202203 92.571 121.301 100.565
202206 407.492 125.017 429.524
202209 213.127 125.227 224.274
202212 49.180 125.222 51.754
202303 48.990 127.348 50.694
202306 40.915 128.729 41.884
202309 35.457 129.860 35.980
202312 24.896 129.419 25.349
202403 5.840 131.776 5.840

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tenax Therapeutics  (FRA:YBO0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Tenax Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (FRA:YBO0) Business Description

Traded in Other Exchanges
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Tenax Therapeutics (FRA:YBO0) Headlines

No Headlines